Exchange: NASDAQ·Updated 04:32 AM EDT
News
all
press releases
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.
Zacks
More News
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.
Zacks
PFE, MRK, SNY, MRNA In Focus As Trump Reportedly Eyes Executive Order On Vaccines And Autism
The order’s contents remain unclear, and timing could shift, Bloomberg reported, citing people familiar with the matter.
Stocktwits
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals
Novavax raised its full-year 2026 adjusted total revenue outlook to $235–$275 million from $230–$270 million.
Stocktwits
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
Zacks
Moderna's mRNA Flu Vaccine Approved By FDA
Moderna's mRNA Flu Vaccine Approved By FDA Authored by Rachel Roberts via The Epoch Times, The U.S. Food and Drug Administration has approved Moderna's flu shot for over-50s, marking the first time the agency has licensed a messenger ribonucleic acid (mRNA) vaccine for seasonal...
Zero Hedge
Antipodes Exited Sanofi (SNY) After Repeated Pipeline Setbacks
Antipodes Exited Sanofi (SNY) After Repeated Pipeline Setbacks...
Yahoo! Finance: News
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full details on earnings and 2026 outlook.read more...
Benzinga
Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks
SNY beats on Q2 earnings and sales as Dupixent tops euro 5B in quarterly sales for the first time. The company also raises its 2026 outlook.
Zacks
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength
REGN's Q2 earnings and revenues beat estimates as robust Eylea HD demand and higher Dupixent profits offset declining Eylea sales.
Zacks

Advertisement|Remove ads.